Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-12.05%
+45.05%
+0.53%
-7.44%
BIIB
Biogen
$116.82
Chart
142.37
139.39
149.02
227.69
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-12.05%
+45.05%
+0.53%
-7.44%
BIIB
Biogen
$116.82
Chart
142.37
139.39
149.02
227.69
BIIB Latest Headlines
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike Avoids Tariff Impact. ) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’.s down from $3.67 a year ago beating .The company sales of $2.43 billion up 6% year over year on a reported basis 8% on constant currency beating the consensus of $2.23 billion.Multiple sclerosis revenue of $953 million decreased by 11% (down 10% on constant currency). The multiple sclerosis drug Tysa
Thu May 1, 2025
BIIBs Q1 Earnings Miss Revenues Top Mark 2025 EPS Guidance Cut. Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
Thu May 1, 2025
Biogens results beat estimates on strength in rare disease drugs.
Thu May 1, 2025
Is Biogen At The Start Of A Turnaround On Its Quarterly Beat?. Biogen stock traded sideways Thursday after the company beat first-quarter expectations including strong sales for two newcomer drugs.The post Is Biogen At The '.Start Of A Turnaround'. On Its Quarterly Beat? appeared first on Investor'.s Business Daily.
Thu May 1, 2025
Biogen Easily Tops Earnings Forecasts As Leqembi Skyclarys Sales Soar. Biogen stock could pop Thursday after the biotech company beat first-quarter expectations including strong sales for two newcomer drugs.The post Biogen Easily Tops Earnings Forecasts As Leqembi Skyclarys Sales Soar appeared first on Investor'.s Business Daily.
Thu May 1, 2025
Biogen: Is This A Value Trap Or Is The Great Turnaround Imminent?.
Fri Apr 25, 2025
14 Analysts Have This To Say About Biogen. 14 analysts have shared their evaluations of Biogen (NASDAQ:) during the recent three months expressing a mix of ish and bearish perspectives.The following table summarizes their recent ratings shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.4370001000001000000042600Analysts'. evaluations of 12-month price targets offer additional insights showcasing an average target of $190.21 with a hig
Tue Apr 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
BIIB Stock trends
BIIB Stock performance
BIIB Stock analysis
BIIB investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Login to display Biogen (BIIB) recommendation from the last 90 days from financial news and social media.
Hover over the category for more information
